Free Trial
LON:POLB

Poolbeg Pharma (POLB) Share Price, News & Analysis

GBX 13.20
0.00 (0.00%)
(As of 05/23/2024 ET)
Today's Range
13.14
13.50
50-Day Range
9.25
14.90
52-Week Range
6.38
15.77
Volume
1.29 million shs
Average Volume
2.23 million shs
Market Capitalization
£66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
POLB stock logo

About Poolbeg Pharma Stock (LON:POLB)

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

POLB Stock Price History

POLB Stock News Headlines

Poolbeg Pharma PLC Announces Director/PDMR Shareholding
Poolbeg Pharma PLC Announces Director Share Purchase
Poolbeg Pharma non-exec steps down from board
Poolbeg Pharma PLC Announces Directorate Change
Poolbeg Pharma lands Japanese patent grant for lead asset
See More Headlines
Receive POLB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poolbeg Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
£-3,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 6.27 per share
Book Value
GBX 3 per share

Miscellaneous

Free Float
N/A
Market Cap
£66 million
Optionable
Not Optionable
Beta
2.16
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Cathal Martin Friel (Age 60)
    Executive Chairman of The Board
    Comp: $138k
  • Dr. Jeremy Skillington Ph.D. (Age 53)
    CEO & Director
    Comp: $310k
  • Mr. Ian O'Connell (Age 37)
    CFO & Director
    Comp: $220k
  • Carol Dalton
    Vice President of Investor Relations & Public Relations
  • Mr. John McEvoy
    Senior Vice President & Chief Legal Officer
  • Mr. David James Allmond (Age 54)
    Chief Business Officer
  • Mr. Salim Gulamabbas Hamir F.C.A.
    Company Secretary
  • Mr. Ross Crockett
    Group Financial Controller

POLB Stock Analysis - Frequently Asked Questions

How have POLB shares performed in 2024?

Poolbeg Pharma's stock was trading at GBX 9.05 on January 1st, 2024. Since then, POLB stock has increased by 45.9% and is now trading at GBX 13.20.
View the best growth stocks for 2024 here
.

How do I buy shares of Poolbeg Pharma?

Shares of POLB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:POLB) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners